JFrog Ltd. Ordinary Shares vs Personalis Inc. Common Stock — how do they compare? JFrog Ltd. Ordinary Shares trades at $91 (market cap $12.24B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 7.2× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 1,786,951). Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 5 Days and Personalis Inc. Common Stock for 0 Days on average.
| FROG | PSNL | |
|---|---|---|
Market Cap | $12.24B | $1.69B |
Volume | 1,786,951 | 3,817,236 |
Sector | Technology | Health |
52-Week High | $104.03 | $18.38 |
52-Week Low | $34.75 | $5.04 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $11.43B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →